CERS News and Press, Cerus Corporation From 02/25/21

Cerus Corporation (CERS) Q4 2020 Results Earnings Conference Call February 25, 2021, 4:30 PM ET Company Participants Matt Notarianni - Senior Director, Investor Relations Obi Greenman - President and CEO Vivek Jayaraman - Chief Operating Officer Kevin Green - Chief Financial Officer Carol Moo...

Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and year ended December 31, 2020. Recent developments and highlights include: Record total fourth quarter and full year 2020 revenues of $33.6 million and $114.2 million, respectively. ...

Cerus (CERS) and Shandong Zhongbaokang Medical Implements form joint venture to develop, manufacture and commercialize the INTERCEPT Blood System for platelets and red blood cells in China.The JV, which will be named "Cerus ZBK Biomedical", will be headquartered in Zibo, S...

Joint Venture Will Enable Cerus to Partner with Leader in Transfusion Medicine to Bring INTERCEPT to the Mainland China Transfusion Market Cerus Corporation (Nasdaq: CERS) and Shandong Zhongbaokang Medical Implements Co. Ltd. (ZBK) today announced that they are forming a joi...

Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full year 2020 financial results will be released on Thursday, February 25, 2021, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during ...

Cerus Corporation ([[CERS]] +0.5%) reports Q4 preliminary sales of $28.2M vs. consensus of $28.16M, an increase of 35% Y/Y representing the highest quarterly product revenue ever reported by Cerus, further taking the full year 2020 sales to $91.9M, exceeding the Company’...

Company also provides 2021 product revenue guidance Cerus Corporation (Nasdaq: CERS) announced today preliminary product revenue for the fourth quarter and full year 2020 and provided 2021 product revenue guidance. Cerus’ unaudited preliminary product revenue for ...

Gainers: [[SOS]] +63.9%. [[XNET]] +23.7%. [[TEN]] +11.2%. [[CERS]] +8.9%. [[SITM]] +8.3%.Losers: [[GBTC]] -8.9%. [[PLYA]] -7.5%. [[UUU]] -6.5%. [[INN]] -6.4%. [[HARP]] -5.8%. For further details see: SOS, XNET, UUU and PLYA among after-hours movers

Cerus' FDA & CE approved Intercept pathogen reduction platform for platelets and plasma gathering momentum as FDA Guidelines require compliance with new blood safety measures by March 31, 2021. Cerus' plans to file for FDA extension of intercept platelet label from 5 to 7-day shel...

Cerus Corporation (Nasdaq: CERS) today announced that its distribution partner, Companhia Energética Integrada (CEI), was awarded a three-year contract with the HemoMinas Foundation (“HemoMinas”) of Brazil for the INTERCEPT Blood System for platelets. HemoMinas provid...